FrancophonIA/ELRC3.0 huggingface dataset:
English: Oprymea 0.52 mg prolonged-release tablets Pramipexole
Estonian: Oprymea 0,52 mg toimeainet prolongeeritult vabastavad tabletid Pramipeksool
English: Oprymea 2.1 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/042 30 prolonged-release tablets: EU/1/08/469/043 90 prolonged-release tablets: EU/1/08/469/044 100 prolonged-release tablets: EU/1/08/469/045
Estonian: Oprymea 2,1 mg toimeainet prolongeeritult vabastavad tabletid 10 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/042 30 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/043 90 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/044 100 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/045
English: Oprymea 1.05 mg prolonged-release tablets Pramipexole
Estonian: Oprymea 1,05 mg toimeainet prolongeeritult vabastavad tabletid Pramipeksool
English: Oprymea 1.57 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/038 30 prolonged-release tablets: EU/1/08/469/039 90 prolonged-release tablets: EU/1/08/469/040 100 prolonged-release tablets: EU/1/08/469/041
Estonian: Oprymea 1,57 mg toimeainet prolongeeritult vabastavad tabletid 10 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/038 30 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/039 90 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/040 100 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/041
English: Posology
Estonian: Maisitärklis
English: Missed dose
Estonian: Võtmata annus
English: EU/1/08/469/042 [10 prolonged-release tablets] EU/1/08/469/043 [30 prolonged-release tablets] EU/1/08/469/044 [90 prolonged-release tablets] EU/1/08/469/045 [100 prolonged-release tablets]
Estonian: EU/1/08/469/042 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/043 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/044 [90 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/045 [100 toimeainet prolongeeritult vabastavat tabletti]
English: Oprymea 1.57 mg prolonged-release tablets Pramipexole
Estonian: Oprymea 1,57 mg toimeainet prolongeeritult vabastavad tabletid Pramipeksool
English: EU/1/08/469/021 [20 tablets] EU/1/08/469/022 [30 tablets] EU/1/08/469/023 [60 tablets] EU/1/08/469/024 [90 tablets] EU/1/08/469/025 [100 tablets]
Estonian: EU/1/08/469/021 [20 tabletti] EU/1/08/469/022 [30 tabletti] EU/1/08/469/023 [60 tabletti] EU/1/08/469/024 [90 tabletti] EU/1/08/469/025 [100 tabletti]
English: EU/1/08/469/011 [20 tablets] EU/1/08/469/012 [30 tablets] EU/1/08/469/013 [60 tablets] EU/1/08/469/014 [90 tablets] EU/1/08/469/015 [100 tablets]
Estonian: EU/1/08/469/011 [20 tabletti] EU/1/08/469/012 [30 tabletti] EU/1/08/469/013 [60 tabletti] EU/1/08/469/014 [90 tabletti] EU/1/08/469/015 [100 tabletti]
English: România KRKA Romania S.R.L., Bucharest
Estonian: Ireland KRKA Pharma Dublin, Ltd.
English: Oprymea 0.26 mg prolonged-release tablets Pramipexole
Estonian: Oprymea 0,26 mg toimeainet prolongeeritult vabastavad tabletid Pramipeksool
English: EU/1/08/469/006 [20 tablets] EU/1/08/469/007 [30 tablets] EU/1/08/469/008 [60 tablets] EU/1/08/469/009 [90 tablets] EU/1/08/469/010 [100 tablets]
Estonian: EU/1/08/469/006 [20 tabletti] EU/1/08/469/007 [30 tabletti] EU/1/08/469/008 [60 tabletti] EU/1/08/469/009 [90 tabletti] EU/1/08/469/010 [100 tabletti]
English: One Oprymea 0.26 mg prolonged-release tablet on blister "Week 1".
Estonian: Ööpäevane annus (mg) Tablettide arv Üks Oprymea 0,26 mg toimeainet prolongeeritult vabastav tablett „Nädal 1“ blistrist.
English: Oprymea 3.15 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/050 30 prolonged-release tablets: EU/1/08/469/051 90 prolonged-release tablets: EU/1/08/469/052 100 prolonged-release tablets: EU/1/08/469/053
Estonian: Oprymea 3,15 mg toimeainet prolongeeritult vabastavad tabletid 10 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/050 30 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/051 90 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/052 100 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/053
English: EU/1/08/469/026 [10 prolonged-release tablets] EU/1/08/469/027 [30 prolonged-release tablets] EU/1/08/469/028 [90 prolonged-release tablets] EU/1/08/469/029 [100 prolonged-release tablets]
Estonian: EU/1/08/469/026 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/027 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/028 [90 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/029 [100 toimeainet prolongeeritult vabastavat tabletti]
English: Oprymea 0.52 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Estonian: Oprymea 0,52 mg toimeainet prolongeeritult vabastavad tabletid on valged või peaaegu valged ümarad (läbimõõduga 10 mm) kergelt kaksikkumerad kaldservade ja võimalike laikudega tabletid, mille ühele küljele on graveeritud P2.
English: Oprymea 1.05 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/034 30 prolonged-release tablets: EU/1/08/469/035 90 prolonged-release tablets: EU/1/08/469/036 100 prolonged-release tablets: EU/1/08/469/037
Estonian: Oprymea 1,05 mg toimeainet prolongeeritult vabastavad tabletid 10 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/034 30 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/035 90 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/036 100 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/037
English: EU/1/08/469/016 [20 tablets] EU/1/08/469/017 [30 tablets] EU/1/08/469/018 [60 tablets] EU/1/08/469/019 [90 tablets] EU/1/08/469/020 [100 tablets]
Estonian: EU/1/08/469/016 [20 tabletti] EU/1/08/469/017 [30 tabletti] EU/1/08/469/018 [60 tabletti] EU/1/08/469/019 [90 tabletti] EU/1/08/469/020 [100 tabletti]
English: Oprymea 0.52 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/030 30 prolonged-release tablets: EU/1/08/469/031 90 prolonged-release tablets: EU/1/08/469/032 100 prolonged-release tablets: EU/1/08/469/033
Estonian: Oprymea 0,52 mg toimeainet prolongeeritult vabastavad tabletid 10 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/030 30 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/031 90 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/032 100 toimeainet prolongeeritult vabastavat tabletti: EU/1/08/469/033
English: Oprymea 2.1 mg prolonged-release tablets Pramipexole
Estonian: Oprymea 2,1 mg toimeainet prolongeeritult vabastavad tabletid Pramipeksool
English: What Oprymea looks like and contents of the pack Oprymea 0.088 mg tablets are white, round, with bevelled edges and imprint "P6" on one side of the tablet.
Estonian: Oprymea 0,088 mg tabletid on valged, ümmargused, kaldservadega tabletid, mille ühele küljele on pressitud „P6”.
English: Oprymea 2.1 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Estonian: Oprymea 2,1 mg toimeainet prolongeeritult vabastavad tabletid on valged või peaaegu valged ümarad (läbimõõduga 10 mm) kergelt kaksikkumerad kaldservade ja võimalike laikudega tabletid, mille ühele küljele on graveeritud P4.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Estonian: Valged või peaaegu valged ümmargused (läbimõõduga 10 mm) kergelt kaksikkumerad kaldservade ja võimalike laikudega tabletid, mille ühele küljele on graveeritud P2.
English: Rare may affect up to 1 in 1,000 people
Estonian: Harv võib esineda kuni 1-l kasutajal 1000-st
English: EU/1/08/469/034 [10 prolonged-release tablets] EU/1/08/469/035 [30 prolonged-release tablets] EU/1/08/469/036 [90 prolonged-release tablets] EU/1/08/469/037 [100 prolonged-release tablets]
Estonian: EU/1/08/469/034 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/035 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/036 [90 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/037 [100 toimeainet prolongeeritult vabastavat tabletti]
English: INNER BOX (week 1)
Estonian: SISEKARP (Nädal 1)
English: Oprymea 1.57 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots.
Estonian: Oprymea 1,57 mg toimeainet prolongeeritult vabastavad tabletid on valged või peaaegu valged ümarad (läbimõõduga 10 mm) kergelt kaksikkumerad kaldservade ja võimalike laikudega tabletid, mille ühele küljele on graveeritud P12.
English: EU/1/08/469/050 [10 prolonged-release tablets] EU/1/08/469/051 [30 prolonged-release tablets] EU/1/08/469/052 [90 prolonged-release tablets] EU/1/08/469/053 [100 prolonged-release tablets]
Estonian: EU/1/08/469/050 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/051 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/052 [90 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/053 [100 toimeainet prolongeeritult vabastavat tabletti]
English: EU/1/08/469/046 [10 prolonged-release tablets] EU/1/08/469/047 [30 prolonged-release tablets] EU/1/08/469/048 [90 prolonged-release tablets] EU/1/08/469/049 [100 prolonged-release tablets]
Estonian: EU/1/08/469/046 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/047 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/048 [90 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/049 [100 toimeainet prolongeeritult vabastavat tabletti]
English: EU/1/08/469/038 [10 prolonged-release tablets] EU/1/08/469/039 [30 prolonged-release tablets] EU/1/08/469/040 [90 prolonged-release tablets] EU/1/08/469/041 [100 prolonged-release tablets]
Estonian: EU/1/08/469/038 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/039 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/040 [90 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/041 [100 toimeainet prolongeeritult vabastavat tabletti]
English: 1 tablet Oprymea 0.18 mg OR
Estonian: Üks Oprymea 0,18 mg tablett VÕI
English: EU/1/08/469/030 [10 prolonged-release tablets] EU/1/08/469/031[30 prolonged-release tablets] EU/1/08/469/032[90 prolonged-release tablets] EU/1/08/469/033[100 prolonged-release tablets]
Estonian: EU/1/08/469/030 [10 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/031 [30 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/032 [90 toimeainet prolongeeritult vabastavat tabletti] EU/1/08/469/033 [100 toimeainet prolongeeritult vabastavat tabletti]
English: 1 tablet Oprymea 0.088 mg
Estonian: Üks Oprymea 0,088 mg tablett
English: Oprymea 1.05 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Estonian: Oprymea 1,05 mg toimeainet prolongeeritult vabastavad tabletid on valged või peaaegu valged ümarad (läbimõõduga 10 mm) kergelt kaksikkumerad kaldservade ja võimalike laikudega tabletid, mille ühele küljele on graveeritud P3.
English: 1 tablet Oprymea 0.35 mg OR
Estonian: Üks Oprymea 0,35 mg tablett
English: If you have advanced Parkinson's disease and are also taking levodopa, you might develop dyskinesia during the uptitration of Oprymea - Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)).
Estonian: - düstoonia (võimetus hoida keha ja kaela sirgena (aksiaalne düstoonia)).
English: Uncommon may affect up to 1 in 100 people
Estonian: Aeg-ajalt võib esineda kuni 1-l kasutajal 100-st
English: 7 tablets of Oprymea 1.05 mg
Estonian: Oprymea 1,05 mg tabletid - 7 tabletti
English: Oprymea 0.18 mg tablets 20 tablets: EU/1/08/469/006 30 tablets: EU/1/08/469/007 60 tablets: EU/1/08/469/008 90 tablets: EU/1/08/469/009 100 tablets: EU/1/08/469/010
Estonian: Oprymea 0,088 mg tabletid 20 tabletti: EU/1/08/469/001 30 tabletti: EU/1/08/469/002 60 tabletti: EU/1/08/469/003 90 tabletti: EU/1/08/469/004 100 tabletti: EU/1/08/469/005
English: INNER BOX (week 3)
Estonian: SISEKARP (Nädal 3)
English: Inform your doctor if you find tablet pieces in your faeces.
Estonian: Juhul kui teie väljaheites esineb tabletitükke, teavitage sellest oma arsti.
English: What Oprymea looks like and contents of the pack Oprymea 0.26 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Estonian: Oprymea 0,26 mg toimeainet prolongeeritult vabastavad tabletid on valged või peaaegu valged ümarad (läbimõõduga 10 mm) kergelt kaksikkumerad kaldservade ja võimalike laikudega tabletid, mille ühele küljele on graveeritud P1.
English: Oprymea is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
Estonian: Oprymea on näidustatud täiskasvanutele idiopaatilise Parkinsoni tõve sümptomaatiliseks raviks ilma levodopata või kombinatsioonis levodopaga kogu haiguse vältel, k.a.
English: 7 tablets of Oprymea 0.52 mg
Estonian: Oprymea 0,52 mg
English: INNER BOX (week 2)
Estonian: SISEKARP (Nädal 2)
English: What measures are being taken to ensure the safe and effective use of Viread?
Estonian: Mis meetmed võetakse, et tagada Vireadi ohutu ja efektiivne kasutamine?
English: Further information on Viread can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/viread.
Estonian: Lisateave Vireadi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/viread.
English: Viread received a marketing authorisation valid throughout the EU on 5 February 2002.
Estonian: Vireadi müügiluba, mis kehtib kogu Euroopa Liidus, anti 5. veebruaril 2002.
English: Moreover, Viread may cause a reduction in bone density.
Estonian: Peale selle võib Viread põhjustada luutiheduse vähenemist.
English: Viread is used in combination with other HIV medicines.
Estonian: Ravimit Viread kasutatakse koos muude HIV-ravimitega.
English: The European Medicines Agency decided that Viread's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Vireadi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Viread (tenofovir disoproxil)
Estonian: Viread (tenofoviirdisoproksiil)
English: What is Viread and what is it used for?
Estonian: Mis on Viread ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Viread are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Vireadi kasutamise kohta pidevat järelevalvet.
English: Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI).
Estonian: Tenofoviir on nukleotiidne pöördtranskriptaasi inhibiitor (NRTI).
English: Viread does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Viread ei tervenda HIV-infektsioonist ega AIDS-ist, kuid võib immuunsüsteemi kahjustumist ning AIDS-iga seotud infektsioonide ja haiguste tekkimist edasi lükata.
English: Other information about Viread:
Estonian: Muu teave Vireadi kohta
English: The figure for the combination treatment of Viread and emtricitabine was 88%.
Estonian: Vireadi ja emtritsitabiini kombinatsioonravi korral oli neid 88%.
English: What are the risks associated with Viread?
Estonian: Mis riskid Vireadiga kaasnevad?
English: Side effects reported with Viread are carefully evaluated and any necessary action taken to protect patients.
Estonian: Vireadi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The company that makes Viread will ensure that all doctors who are expected to prescribe or use Viread in children are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones.
Estonian: Vireadi turustaja tagab, et kõikidele ravimit Viread määravatele või kasutavatele arstidele antakse teabematerjalid, mis sisaldavad olulist ohutusteavet, eelkõige neerutalitluse ja luudega seotud riskide ja ettevaatusmeetmete kohta.
English: For more information about using Viread, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Vireadi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: In children and adolescents it is only used in patients who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI).
Estonian: Lastel ja noorukitel kasutatakse seda ainult neil patsientidel, keda ei saa ravida muude esmavaliku nukleotiidse pöördtranskriptaasi inhibiitoritega.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Viread have also been included in the summary of product characteristics and the package leaflet.
Estonian: Vireadi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Although it showed no benefit of adding Viread to existing treatment compared with adding placebo, Viread produced similar levels of the active substance in the body compared to adults, and it was judged that the results were influenced by the type of patients included in the Viread group.
Estonian: Kuigi selgus, et Vireadi lisamine olemasolevale ravile ei olnud kasulikum kui platseebo lisamine, tekitas Viread organismis toimeaine sama sisalduse kui täiskasvanutel, ning arvati, et tulemusi mõjutas Vireadi rühma kaasatud patsientide sihtpopulatsioon.
English: For patients who have taken medicines to treat HIV infection before, doctors should only prescribe Viread once they have looked at the antiviral medicines the patient has taken before or the likelihood that the virus will respond to antiviral medicines.
Estonian: Kui patsient on HIV-nakkuse vastaseid ravimeid varem kasutanud, võib arst määrata ravimit Viread üksnes siis, kui ta on võtnud arvesse patsiendi varem kasutatud viirusravimeid ning viiruse ravimitele reageerimise tõenäosust.
English: The most common side effects with Viread (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, diarrhoea, dizziness, hypophosphataemia (low levels of phosphate in the blood), rash and asthenia (weakness).
Estonian: Vireadi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus, oksendamine, kõhulahtisus, peapööritus, hüpofosfateemia (vere väike fosfaadisisaldus), lööve ja asteenia (nõrkus).
English: Viread, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Koos teiste viirusravimitega manustatav Viread vähendab HIV-i kogust veres ja hoiab selle sisalduse väikese.
English: Viread is a medicine used to treat patients aged 2 years and above infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Viread on viirusravim, mida kasutatakse selliste vähemalt 2-aastaste patsientide raviks, kes on nakatunud 1. tüüpi inimese immuunpuudulikkuse viirusega (HIV-1), mis põhjustab omandatud immuunpuudulikkuse sündroomi (AIDS).
English: For the full list of side effects and restrictions with Viread, see the package leaflet.
Estonian: Vireadi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Viread stops the virus making DNA and prevents it from multiplying and spreading.
Estonian: Lamivudiin peatab viiruse DNA moodustumise ning takistab selle kordistumist ja levikut.
English: In adults, it can also be used for those patients with liver damage whose liver is not working properly (decompensated liver disease) and those patients who do not respond to treatment with lamivudine (another medicine for hepatitis B infection).
Estonian: Täiskasvanutel tohib ravimit Viread kasutada ka sellistel maksakahjustusega patsientidel, kelle maksatalitlus ei ole korras (dekompenseeritud maksahaigus), ja patsientidel, kellele ei mõju ravi lamivudiiniga (samuti B-hepatiidi ravim).
English: A study carried out in 87 adolescents (12 to 18 years of age) investigated the effects of adding Viread to existing treatment.
Estonian: Uuringus, mille osales 87 noorukit (12-18 a), uuriti Vireadi toimet, kui seda lisati olemasolevale ravile.
English: Viread is also used to treat chronic (long-term) hepatitis B virus infection in adults and children aged 2 years and above with liver damage whose liver is still working properly (compensated liver disease).
Estonian: Ravimit Viread kasutatakse ka kroonilise (pikaajalise) B-hepatiidi viirusinfektsiooni raviks maksakahjustusega täiskasvanutel ja vähemalt 2-aastastel lastel, kelle maksatalitlus on veel korras (kompenseeritud maksahaigus).
English: For the treatment of hepatitis B, two studies involving 641 adult patients compared Viread with another medicine, adefovir dipivoxil.
Estonian: Kahes B-hepatiidi raviuuringus, milles osales 641 täiskasvanud patsienti, võrreldi ravimit Viread teise ravimiga (adefoviirdipivoksiil).
English: Rare cases of severe kidney problems have also been seen in patients treated with Viread.
Estonian: Vireadiga ravitud patsientidel on harvadel juhtudel esinenud ka raskeid neerutalitluse probleeme.
English: How is Viread used?
Estonian: Kuidas ravimit Viread kasutatakse?
English: What benefits of Viread have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vireadi kasulikkus?
English: An overview of Viread and why it is authorised in the EU
Estonian: Ülevaade ravimist Viread ja ELis müügiloa väljastamise põhjendus
English: It showed that the majority of those who switched treatment from stavudine or zidovudine maintained their low HIV blood levels on Viread (83% of children in the Viread group and 92% of those on stavudine or zidovudine had viral loads below 400 copies/ml after 48 weeks).
Estonian: Uuring tõendas, et enamik neist, kellel vahetati stavudiin- või zidovudiin-ravi, säilitasid vere väikse HIV-sisalduse, kui nad kasutasid ravimit Viread (83%-l lastest Vireadi rühmas ja 92%-l stavudiini või zidovudiini rühmas oli viiruskoormus alla 400 koopia/ml pärast 48 nädalat).
English: Tenofovir also interferes with the action of an enzyme produced by the hepatitis B virus called DNA polymerase, which is involved in the formation of viral DNA.
Estonian: Lisaks häirib tenofoviir B-hepatiidi viiruse tekitatava ja viiruse DNA moodustumises osaleva ensüümi DNA-polümeraasi toimet.
English: The dose may need to be reduced or the medicine given less often in patients who have moderately or severely reduced kidney function.
Estonian: Mõõduka või raske neerutalitlushäirega patsientidel võib olla vaja annust vähendada või võtta ravimit harvem.
English: In a third study involving 112 adults whose liver had stopped working properly (decompensated liver disease) Viread was compared with entecavir and a combination treatment of Viread and emtricitabine.
Estonian: Kolmandas uuringus, milles osales 112 täiskasvanut, kelle maksatalitlus oli puudulik (dekompenseeritud maksahaigus), võrreldi ravimit Viread entekaviiriga ning Vireadi ja emtritsitabiini kombinatsioonraviga.
English: Two studies involving 741 HIV-infected adults showed that Viread resulted in a fall in the levels of HIV in the blood (viral load) of around 75% after 4 and after 24 weeks, compared with a small rise or fall in viral load of around 5% in the patients taking placebo.
Estonian: Kaks uuringut, milles osales 741 HIV-iga nakatunud täiskasvanut, tõendasid, et Viread vähendas vere HIV-sisaldust (viiruskoormus) ligikaudu 75% pärast 4 ja pärast 24 nädalat, võrreldes viiruskoormuse väikese suurenemise või vähenemisega (ligikaudu 5%) platseebot kasutanud patsientidel.